EANS-Adhoc: SYGNIS Pharma AG / SYGNIS Pharma AG secures further financial resources with shareholder loan

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

15.06.2011

Ad-hoc

SYGNIS Pharma AG secures further financial resources with shareholder
loan

Heidelberg, 15 June 2011 - SYGNIS Pharma AG (Frankfurt:
LIOK; ISIN DE000A1E9B74; Prime Standard) today executed a
subordinated loan agreement for a total amount of EUR 6 million
with its main shareholder dievini Hopp BioTech holding GmbH & Co.
KG, Walldorf, Germany (dievini), with an interest-rate at
customary market conditions. As a result this loan, which is payable
on demand, secures the financing of SYGNIS´ existing operations,
according to the present plans, at least until the end of 2012.

The loan is unsecured, bears no expiry date and may be terminated not
before 30 September 2012. In this case the loan is to be repaid
within a one month period. The loan agreement will be dissolved
through dievini´s corresponding participation in a future
capital increase with shareholders subscription rights. In
addition, instead of requesting a repayment of the loan, dievini is
entitled to a repayment by way of a contribution in kind as part of
a capital increase with shareholders subscription rights.
Alternatively repayment can be made in return for shares by way of
a convertible bond programme, which is yet to be agreed upon.
Prerequisite for these repayment options are the resolution and
execution of a capital increase with shareholders subscription rights
or a convertible bond programme as well as the creation of the
conditional capital necessary for the second option through
decision of SYGNIS´ Annual General Meeting and registration in
the commercial register.

For further information please contact:

|Peter Willinger |
|CFO |
|Tel: +49 (0) 6221-454 836 |
|Email: peter.willinger@sygnis.de |
| |

###

Disclaimer Some statements included in this press release, relating
neither to proven financial results nor other historical data, should
be viewed as forward- looking, i.e. not definite. Such statements are
mainly predictions of future results, trends, plans or goals. These
statements should not be considered to be total guarantees since
given their very nature they are subject to known and unknown risks
and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS
Pharma AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not
undertake to publicly update or revise these statements in the light
of new information or future results or for any other reason. ###

Further inquiry note:
Michael Wolf
Telefon: +49 (0) 6221 454 - 745
E-Mail: Michael.Wolf@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English